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Approximately 8% o f all couples are infertile.
It is estimated that 15% to 20% o f all recognized pregnancies end in spontaneous abortions.
O f the 3 million infants born during the 1980s, approximately 7% were low birth weight, 5% were preterm, 2% to 3% had major congenital anomalies, and an unknown number have developmental or functional problems in childhood.
The extent to which environmental or occupational exposures affect these statistics is unknown.
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How to use this issue...
This issue begins with a composite case study that describes realistic encounters with patients. The case study is 
followed by a pretest. (Answers to the Pretest questions are on pages 13-16.) The monograph ends with a posttest, 
which can be submitted to the Agency for Toxic Substances and Disease Registry (ATSDR) for continuing medical 
education (CME) credit or continuing education units (CEU). See page 39 for further instructions on how to receive 
these credits.
The objectives of this monograph on reproductive and developmental hazards are to help you
□  Describe the factors that may adversely affect reproduction and fetal development
□  Identify adverse reproductive and developmental outcomes that may be caused 
by environmental or occupational exposures
□  Identify evaluation and treatment protocols for adverse reproductive and 
developmental outcomes
□  List sources of information on reproductive and developmental hazards
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From an article in your local newspaper, you learn that an underground waste solvent storage tank at a local 
semiconductor manufacturing plant is leaking toxic chemicals. According to the plant manager, the tank, which 
contains mostly 1,1,1 -trichloroethane (TCA), is located about 2000 feet from a well that supplies drinking water 
to a nearby residential area. The article also mentions that at the time the leak was discovered, the 
concentration of TCA inthe well was 1700 ppb. The well was immediately removedfrom service. The newspaper 
article states that as reporters interviewed residents for the story, they were told about five cases of 
spontaneous abortion and four cases of cardiac defects in the area.
Two weeks later, TCA levels in the well reached 8800 ppb, and minor amounts of 1,1-dichloroethylene (DCE) 
were found. Eighteen of your patients received water from the contaminated well, and several of them, including 
a 30-year-old pregnant patient, have requested consultations with you. After listening to their concerns, you 
contact the Agency for Toxic Substances and Disease Registry (ATSDR) to request assistance. In the health 
consultation provided, ATSDR concludes that the levels are far above levels established to protect public 
health; however, no human epidemiologic studies have been reported that adequately address reproductive 
effects caused by TCAor DCE. Data from animal studies do not suggest adverse reproductive ordevelopmental 
outcomes from ingestion of these chemicals.
ATSDR decides to conduct a Public Health Assessment for this site. While collecting information for the health 
assessment, ATSDR finds that birth certificates for the county do not reveal an excess of adverse pregnancy 
outcomes in the water-service area compared with the rest of the county. However, because only 20% of all 
birth defects are typically reported on birth certificates, the agency advises that birth certificate studies alone 
cannot rule out an increase of birth defects; furthermore, vital records do not provide data on spontaneous 
abortions.
Currently, ATSDR is developing a protocol for an epidemiologic study to determine whether an association 
exists between exposure to the contaminated well water and congenital anomalies and spontaneous abortions. 
Pending the outcome of the epidemiologic study, you must communicate the risk of adverse reproductive and 
developmental effects due to toxic exposures. How will you address the following questions from your patient 
who is pregnant and her neighbors?
(a) Can adverse reproductive effects such as spontaneous abortion and birth defects be caused 
by drinking and using contaminated well water?
(b) I am 3 months pregnant. How will this exposure affect my pregnancy?
(c) Can I breast-feed if I have been drinking the contaminated water?
(d) My wife is having trouble getting pregnant; could this chemical exposure be responsible?
(e) We are planning to become pregnant; is it safe to do so?
(f) What is the health consultation provided by ATSDR? What is a public health assessment?
Answers to the Pretest questions are on pages 13-16.
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The Magnitude of the Problem
□  About one in twelve couples 
of reproductive age in the 
United States is infertile.
□  At least 40% of all 
conceptions are lost 
before the 28th week of 
gestation.
□  Many chemical agents are 
suspected of causing 
adverse reproductive or 
developmental effects; 
however, strong evidence 
exists for only a few.
□  Folic acid supplements 
administered during the 
periconceptual period may 
prevent fetal CNS anomalies.
Several adverse reproductive effects can result from exposure of 
men and women to biologic, chemical, or physical hazards. Dam­
age to the male or female germ cells can reduce fertility, and 
exposure before or during gestation can cause early pregnancy 
loss (clinically manifested as menstrual irregularity or infertility), 
spontaneous abortion, preterm or low-birth-weight neonates, birth 
defects, abnormal growth and development, and carcinogenesis 
(manifested as childhood cancer). Accurate data on reproductive 
and developmental effects are limited by the intrinsic difficulty of 
diagnosis and the lack of a national data collection system. Never­
theless, some estimates of adverse reproductive and developmen­
tal outcomes in the United States have been made.
About one in twelve couples of reproductive age in the United States 
is infertile. (A couple is deemed infertile if conception has not 
occurred after 1 yearof unprotected sexual intercourse.) At least 40% 
of all conceptions are lost before the 28th week of gestation. About 
2% to 3% of all newborns (approximately 3 million during the 1980s) 
have major congenital anomalies, 7% are low birth weight, 5% are 
preterm, and an undetermined number have developmental or 
functional problems in childhood. The causes of most of these 
adverse outcomes are unknown. If even a small percentage of these 
effects is attributable to environmental or occupational exposures, 
the number of families affected is large.
Chemical Agents and Adverse Outcomes
To cause reproductive or developmental harm, toxicants must be 
absorbed into the bloodstream and pass from the blood to the 
reproductive organs or through the placenta to the fetus. Many 
chemical hazards react with the first tissues they contact—eyes, 
nose, throat, lungs, or skin— and rarely enter the bloodstream. 
Hence, these substances are unlikely to affect reproduction orfetal 
development. The following are examples of substances that are 
unlikely to enter the bloodstream in significant amounts, except 
when ingested.
ammonia 
asbestos 
chlorine 
fiberglass 
hydrochloric acid 
nitric acid
Much of what we know about chemical exposures and their effects 
on reproduction and fetal development is from research using 
experimental animals. Effects of an absorbed toxicant may vary 
among the animal species and even among different strains of the 
same species. Extrapolating positive findings from animal studies
potassium hydroxide 
silica
sodium hydroxide 
sodium hypochlorite (bleach) 
sulfuric acid
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Reproductive and Developmental Hazards
to humans involves great uncertainty, and negative animal studies 
do not necessarily mean a compound poses no risk to humans. 
Differences in species response can be due to genetic variability, to 
differences in absorption and metabolism (including activation of the 
toxicant), or to different types of interactions within cells and tissues. 
Thalidomide, which has no detectable effect on mouse embryos but 
caused limb deformities in humans and higher primates, illustrates 
the variability of response among species.
Most human data are from exposures that occurred in the workplace, 
but in many cases, the data are inconclusive or difficult to interpret. 
Strong positive associations between a hazard and reproductive or 
developmental effects have been found for only a few substances 
including lead, mercury, certain organic chemicals (e.g., ethanol and 
ethylene oxide), and ionizing radiation. Certain biologic agents (e.g., 
rubella and mumps) are also strongly associated with adverse 
reproductive or developmental outcomes. Tobacco smoke has been 
reported to reduce fertility in both males and females.
Table 1 lists some environmental or occupational agents suspected to 
cause decreased female reproductive capacity or adverse develop­
mental effects in the fetus. Some therapeutic agents reported to affect 
female reproductive capacity include steroids, alkylating agents, 
methotrexate, levodopa, quinacrine, appetite suppressants, opioids, 
antipsychotics (e.g., phenothiazines), antidepressants (e.g., 
imipramine, amitriptyline, and monoamine oxidase inhibitors), sero­
tonin, sympathomimetic amines (e.g., epinephrine, norepinephrine, 
amphetamines), and reserpine.
Antifolate agents have been associated with macroscopic malforma­
tions in the fetus, especially central nervous system anomalies. 
Malformations have included spina bifida, hydrocephaly, anen- 
cephaly, and meningoencephalocele. To reduce the risk of having a 
pregnancy affected with neural tube defects (NTDs), the United 
States Public Health Service recommends that all women of repro­
ductive age consume 0.4 milligrams (mg) of folic acid per day. 
Principal dietary sources of this vitamin include green, leafy veg­
etables, broccoli, spinach, mushrooms, liver, nuts, dried beans, 
peas, egg yolk, and whole-wheat bread. A varied diet that includes 
fresh vegetables and fruits generally provides enough folic acid for 
the body’s needs. However, women who have had a prior NTD- 
affected pregnancy are at high risk of having a subsequent affected 
pregancy. In 1991, the Centers for Disease Control and Prevention 
(CDC) recommended that these high-risk women who are planning 
to become pregnant consult their physicians about taking 4.0 mg of 
folic acid per day during the periconceptual period (1 month before 
conception to 3 months after).
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Table 1. Agents associated with adverse female reproductive capacity or developmental effects In 
human and animal studies*
Agent Human Outcomes Strength of
Association 
in Humans
Animal Outcomes Strength of 
Association 
in Animals
Anesthetic gases^ Reduced fertility, 
spontaneous abortion 1,3 Birth defects 1,3
Arsenic Spontaneous abortion, 
low birth weight
NA §
Birth defects, fetal loss 2
Benzo(a)pyrene None Birth defects 1
Cadmium None NA Fetal loss, birth defects 2
Carbon disulfide Menstrual disorders, 
spontaneous abortion 1 Birth defects 1
Carbon monoxide Low birth weight, 
fetal death (high doses) 1
Birth defects 
neonatal mortality 2
Chlordecone None NA Fetal loss 2,3
Chloroform None NA Fetal loss 1
Chloroprene None NA Birth defects 2,3
Ethylene glycol ethers Spontaneous abortion 1 Birth defects 2
Ethylene oxide Spontaneous abortion 1 Fetal loss 1
Formamides None NA Fetal loss, birth defects 2
Inorganic mercury ^ 
Lead ^
Menstrual disorders, 
spontaneous abortion 1 Fetal loss, birth defects 1
Spontaneous abortion, prematurity, 
neurologic dysfunction in child 2 Birth defects, fetal loss 2
Organic mercury CNS malformation, cerebral palsy 2 Birth defects, fetal loss 2
Physical stress Prematurity 2 None NA
Polybrominated biphenyls 
(PBBs) None NA Fetal loss 2
Polychlorinated biphenyls 
(PCBs)
Neonatal PCB syndrome 
(low birth weight, hyperpig­
mentation, eye abnormalities) 2 Low birth weight, fetal loss 2
Radiation, ionizing Menstrual disorders,
CNS defects, skeletal &
eye anomalies, mental retardation,
childhood cancer 2 Fetal loss, birth defects 2
Selenium Spontaneous abortion 3 Low birth weight, birth defects 2
Tellurium None NA Birth defects 2
2,4-Dichlorophenoxy acetic 
acid (2,4-D) Skeletal defects 4 Birth defects 1
2,4,5-T richlorophenoxyacetic 
acid (2,4,5-T) Skeletal defects 4 Birth defects 1
Video display terminals 
Vinyl chloride
Spontaneous abortion 4 Birth defects 1
CNS defects 1 Birth defects 1,4
Xylene Menstrual disorders, fetal loss 1 Fetal loss, birth defects 1
* Major studies of the reproductive health effects of exposure to dioxin are currently in progress.
t  1 = limited positive data. 3 = limited negative data.
2 = strong positive data. 4 = strong negative data.
§ Not applicable because no adverse outcomes were observed.
H Symbol used to designate agents that may have male-mediated effects.
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Toxicology of Reproductive Function
Germ Cell Development
Female. Oogonia develop in the female during fetal life when they □  
undergo the first meiotic division. As a result, a wom ar s born with 
a full complement of oocytes. Through natural processes, the num­
ber of oocytes decreases from a maximum of abou t7 million in the 
5th gestational month to about 400,000 at puberty. Oi y 300 to 500 of 
the oocytes remaining at puberty will mature during a woman’s 
reproductive life span.
The oocytes rest in the ovary until ovulation occurs, which for some 
oocytes may be 45 years or more after formation. At the start of the 
menstrual cycle, a group of small primary follicles b e r  ns to develop, 
each containing an oocyte. Release of pituitary folliuti-stimulating 
hormone (FSH) supports the selection and growth of a dominant 
follicle; the remaining follicles degenerate. The growing follicle ^  
produces estrogen, which causes proliferation of endometrial tissue.
When a critical blood concentration of estrogen is reached, the 
anterior pituitary releases a mid-cycle burst of hormones (FSH and 
luteinizing hormone [LH]), causing the follicle to rupture and ovulation 
to occur. The remaining cells of the ruptured follicle form the corpus 
luteum.
Fertilization can occur within 12 hours after ovulation. In the absence 
of fertilization, the corpus luteum degenerates. The consequent 
decrease in ovarian steroids produces ischemia and sloughing of the 
endometrium, resulting in menstruation. If fertilized, the ovum com­
pletes a second meiotic division, forming a zygote that undergoes 
several rapid cell divisions to become a blastocyst. The blastocyst 
implants in the endometrium approximately 5 days after fertilization.
Because many opportunities for exposures exist throughout a 
woman’s life and there is no mechanism for reproductive regenera­
tion, the potential for damage to the oocytes is significant. Research­
ers are elucidating the mechanisms by which oocyte damage or loss 
occurs; however, no studies have documented an association 
between exposure to industrial chemicals and oocyte damage or 
loss, which can cause infertility or premature menopause.
Male. In contrast to oocyte formation, spermatozoa are in continual 
production in stem cells after puberty. In humans, spermatozoa 
mature in an average cycle length of 74 days.
At precise intervals, primitive spermatogonia in the testes proceed 
from the basement membrane to the lumen of the seminiferous 
tubule where they undergo mitotic and meiotic cell divisions. Each 
germ cell duplicates itself (meiosis I), and each resulting diploid cell
Females are born 
with a full complement of 
oocytes. In contrast, 
spermatozoa are in 
continual development in 
males after puberty.
Because reproductive 
regeneration does not 
occur in females, the 
ramifications of oocyte 
damage are significant.
Chemical exposures to males 
can cause adverse pregnancy 
outcomes by several 
mechanisms.
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□  Reproductive function in 
both men and women 
depends on the endocrine 
cycle, which is sensitive to 
physical and chemical 
agents.
(46 chromosomes) divides into two haploid cells with 23 chromosomes 
each (meiosis II). Haploid cells then undergo spermiogenesis, devel­
oping a head, midpiece, and tail. The head consists of the sperm 
nucleus and the acrosome that contains the enzymes necessary for 
egg penetration.
After leaving the testes, sperm acquire motility and fertilizing capacity 
during transit through the epididymis and vas deferens. Sperm trans­
port is dependent on the production of seminal fluid by the seminal 
vesicles. Sertoli cells in the testes play an important role in initiating 
spermatogenesis, synthesizing essential proteins, and providing 
nurturance. Supporting Leydig cells manufacture and secrete testos­
terone, which helps to maintain spermatogenesis and is essential for 
sexual interest and activity.
Exposure to ionizing radiation (alpha, beta, and gamma radiation; 
X rays), heat, or certain chemicals (Table 2) has been documented to 
cause male infertility and decreased libido. Destruction of the basic 
s tem -ce ll sperm atogon ia  usua lly  causes perm anent in fe rtility ; 
damage during subsequent stages of the maturation process is 
potentially reversible. Chemical exposure to the male can cause 
adverse pregnancy outcomes not only by damaging the sperm, which 
can produce an abnormal zygote, but possibly also by transmission 
of toxic agents in seminal fluid. In addition, contaminated skin and 
clothing of the male is a potential source of toxicant exposure to 
the pregnant woman.
Endocrine Function
Reproductive function in men and women depends on the functioning 
of the neuroendocrine system. For men, FSH from the pituitary and 
testosterone from the Leydig cells of the testes act upon the Sertoli 
cells to initiate spermatogenesis. Pituitary LH induces high intra- 
testicular concentrations of testosterone. For women, reproductive 
function requires pituitary LH and FSH, ovarian and adrenal estrogen, 
and progesterone.
Endocrine functioning in both men and women can be interrupted by 
agents with steroid-like activity or by neurologic effects induced by 
stress. Disorders of circadian rhythm, as can occur with some types of 
rotating work schedules, can also affect the endocrine cycle. The 
clinical results may be menstrual disorders in women and disorders of 
libido in both sexes.
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Table 2. Exposures associated with male reproductive dysfunction
Agent Human Outcomes Strength of 
Association 
in Humans*
Animal Outcomes Strength of 
Association 
in Animals*
Boron Decreased sperm count 1 Testicular damage 2
Benzene None NAt Decreased sperm motility, 
testicular damage 1
Benzo(a)pyrene None NA Testicular damage 1
Cadmium 
Carbon disulfide
Reduced fertility 
Decreased sperm count,
1 Testicular damage 2
decreased sperm motility 2,3 Testicular damage 1
Carbon monoxide None NA Testicular damage 1
Carbon tetrachloride None NA Testicular damage 1
Carbaryl
Chlordecone
Abnormal sperm morphology 1 
Decreased sperm count,
Testicular damage 1
Chloroprene
decreased sperm motility 
Decreased sperm motility, 
abnormal morphology,
2 Testicular damage 2
Dibromochloropropane
(DBCP)
decreased libido 
Decreased sperm count, 
azoospermia,
2 Testicular damage 1
Dimethyl dichlorovinyl
hormonal changes 2 Testicular damage 2
phosphate (DDVP) None NA Decreased sperm count 2
Epichlorohydrin None NA Testicular damage 2,3
Estrogens Decreased sperm count 2 Decreased sperm count 2
Ethylene oxide None NA Testicular damage 1
Ethylene dibromide (EDB) Abnormal sperm motility 1 Testicular damage 2,3
Ethylene glycol ethers Decreased sperm count 1 Testicular damage 2
Heat Decreased sperm count 2 Decreased sperm count 2
Lead
Manganese
Decreased sperm count 
Decreased libido,
2 Testicular damage, 
decreased sperm count, 
decreased sperm motility, 
abnormal morphology 2
Polybrominated biphenyls
impotence 1 Testicular damage 1,3
(PBBs)
Polychlorinated biphenyls
None NA Testicular damage 1
(PCBs) None NA Testicular damage 1
Radiation, ionizing Decreased sperm count 2
* 1 = limited positive data. 3 = limited negative data. 
2 = strong positive data. 4 = strong negative data.
t  Not applicable because no adverse outcomes were observed.
Testicular damage 2
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□  The major organ systems 
of the human embryo 
develop during the third 
to ninth week of 
gestation.
□  It is uncertain whether a 
threshold exists for all 
teratogens.
Developmental Biology
Soon after the blastocyst implants in the endometrium, trophoblastic 
cells rapidly proliferate, invading the uterine decidua and its vascu­
lature. Placental circulation, which provides nutrient transport, is 
established by about the 17th day after ovulation. Substances that 
are of low molecular weight, lipophilic, and nonionized at physiologic 
pH readily diffuse across the placenta. The embryonic stage of 
development begins about the third week after ovulation. During the 
ensuing six weeks, the major organ systems of the embryo (i.e., 
cardiovascular, central nervous system, genitourinary, respiratory, 
endocrine, and immune system) form in a precisely timed sequence. 
Dramatic growth and maturation then continues during the remain­
ing fetal period, until birth, when the average fetus weighs about 3000 
to 3600 grams (about 6.6 to 8.0 pounds).
Exposures during weeks 1 and 2 after conception (i.e., the period of 
rapid division of the zygote, implantation, and formation of the 
bilaminar embryo) may cause early pregnancy loss by interfering 
with tubal transport or implantation. Heavy metals such as lead or 
copper have been found to inhibit implantation in experimental 
animals by interfering with uterine hormone-binding mechanisms.
Teratogenic effects usually occur during the critical periods of organo­
genesis. Different agents given at the same critical period can cause 
the same anomaly, and the same agent administered at different 
periods of organogenesis may cause different anomalies. An insult 
delivered just before or during the early stages of the development of 
a particular organ is most likely to render the organ abnormal. (See 
Table 3 for a list of agents and conditions that are teratogenic in 
humans.) Thalidomide taken by humans between the 27th and 29th 
day of pregnancy caused limb deformities.
Table 3. Known or suspected human teratogens
Chemicals/Drugs
Aminopterin
Androgenic hormones
Antithyroid drugs
Busulfan
Chlorobiphenyls
Coumarin anticoagulants
Cyclophosphamide
Diethylstilbestrol
Diphenylhydantoin
Lithium
Mercury, organic 
Methlmazole 
13-cls-Retinoic acid 
Tetracyclines 
Trimethadlone
Radiation
Atomic weapons
Radioiodine
Radiotherapy
Infectious agents
Cytomegalovirus 
Hepatitis B virus 
Herpes simplex virus 
Rubella virus
Treponema pallidum (syphilis) 
Toxoplasma '•ondii 
Varicella virus (chicken pox) 
Venezuelan equine encephalitis virus
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Thus, the timing of an exposure often determines its effect. In the first
2 weeks after conception, when organogenesis has not yet begun, 
the most probable effect of significant exposure is severe damage 
and death of the embryo; that is, immediate postconception expo­
sures do not usually result in specific birth defects. The period from
3 to 9 weeks postconception is a critical time when classic birth 
defects can be induced (Figure 1). Growth deficits, minor morphologic 
abnormalities, and postnatal functional abnormalities typically 
occur after 9 weeks of gestation. Carcinogens potentially can exert 
an effect at any stage in development.
Figure 1. Periods of sensitivity* for major organ systems
Embryonic period Fetal period
(weeks 3 to 8 postconception) (weeks 8 to 38 [full term])
Organ 3 4 5 6 7 8 12 16 20-36 38
CNS xxxxxxxxxxxxxxxxxxxxxxxxx
Heart xxxxxxxxxxxxxxxxxxxxxxxxx
Limbs xxxxxxxxxxxxxxxxxxxxxx------------
Ear xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx— ------
Eyes xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx---------
Teeth xxxxxxxxxxxxxxxxxx---------
Palate xxxxxxxxxxxxxxxxxx
External genitalia xxxxxxxxxxxxxxxxxxx
* period of high sensitivity = xxxxxx; period of less sensitivity = —
Adapted from Hays DP, Pagliaro LA. Human teratogens. In: Pagliaro LA, Pagliaro AM, eds. Problems in pediatric drug 
therapy. Hamilton, IL: Drug Intelligence Publications, 1987.
Some chemical toxicants cause severe effects on the embryo and 
have no effect on the pregnant woman; others affect the embryo only 
at maternally toxic doses. Traditional theory contends that a thresh­
old exists for defects of organogenesis because the embryo can 
usually repair damage caused by low levels of exposure. Exposure 
must occur above the threshold to cause damage. However, recent 
studies of the fetal metabolism of xenobiotics suggest that a thresh­
old may not exist for all substances; for example, no threshold has 
been defined for carcinogens.
A toxic agent may affect the embryo even when exposure occurred to 
the mother or father before conception. In some cases, damage to 
genetic material in the ovary or sperm (mutagenesis) results in 
pregnancy loss or inheritable defects in offspring. In other cases, 
exposure before conception affects the development of the fetus 
because the toxicant persists in the maternal body. For example, 
polychlorinated biphenyl (PCB) compounds are stored in adipose 
tissue for a significant period of time, and lead may be stored in bone
9
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for years. Toxicants generally reach a steady state between the 
storage depot and the blood, but the stresses of pregnancy may 
cause the toxicant level in the bloodstream to increase. The fetus 
may be exposed to these body stores through maternal circulation.
Toxicants can also be passed to the infant through breast feeding. 
Transfer of chemicals into breast milk occurs primarily by passive 
diffusion. Table 4 lists the milk-to-maternal plasma ratios for several 
toxicants; substances with ratios greater than one tend to be highly 
lipophilic and nonpolar molecules. High maternal exposures, such 
as those caused by the ingestion of PCB-contaminated rice oil in 
Japan in 1968, have led to disease in infants, either through expo­
sure in utero or through breast feeding. Chemical exposures by 
routes other than maternal ingestion have not been reported to 
produce adverse health effects in breast-fed infants.
Table 4. Milk-to-maternal plasma ratios in exposed women
Chemical Milk/Plasma Ratio
Mercury, Inorganic and organic , 0.9
Lead < 1.0
Tetrachloroethylene 3.0
Polybrominated biphenyls (PBBs) 3.0
Polychlorinated biphenyls (PCBs) 4.0-10.0
Dieldrin 6.0
o,p-Dichlorodiphenyltrichloroethane (DDT) residues 6.0-7 .0
Adapted from Wolff MS. Occupationally derived chemicals in breast milk. Am J Ind Med 1983;4:259-281.
Management
Male infertility secondary to occupational exposure may be revers­
ible because of the capacity of the male to regenerate sperm. In men 
chronically exposed to i,2-dibromo-3-chloropropane(DBCP), recov­
ery occurred in those with oligospermia (a subnormal concentration 
of spermatozoa in the semen), although it required as long as 
18 months in some cases. However, in men exposed to doses of 
DBCP that caused azoospermia (absence of living spermatozoa in 
the semen), long-term sterility resulted. In addition to changes in 
sperm counts in DBCP-exposed workers, testicular biopsy revealed 
atrophy of the seminiferous epithelium or tubular hyalinization with 
few germ cells, and in some tubules only Sertoli cells persisted. 
These histopathologic changes were associated with elevated LH 
and FSH plasma levels and decreased testosterone levels. Follow- 
up studies of DBCP-exposed workers showed recovery was directly 
linked to FSH levels (i.e., greater recovery occurred in men whose 
FSH levels were normal). Data from patients treated with high-dose 
therapeutic radiation suggest that even azoospermia can be re­
versed in some cases, but recovery may take 4 to 5 years. (Acute 
exposure to lower doses of radiation [-15 rads] affects spermatoge­
nesis only transiently.)
□  Infertility secondary to 
chemical exposure 
may be reversible in 
males because of 
continuous sperm 
production.
□  The effects of chemical 
exposures on female 
fertility are unknown in 
most cases.
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Volume, standardized count, motility, and morphology analysis 
should be performed on two semen samples to make a diagnosis of 
male infertility. Normal values for semen analysis are listed in Table 5. 
No clear guidelines are available on how much of a change in semen 
parameters constitutes significant improvement. Although 20 million 
sperm per milliliter (mL) of semen is traditionally ac-epted as a 
minimal sperm count, conception can occur with counts below this 
value, and some men who have higher counts may still be infertile. 
An improvement in the sperm count from 5 million to 40 million 
per mL is clinically significant, but a change from 10 million to 
15 million per mL is probably not. Consultation with a fertility expert 
may be helpful.
Table 5. Normal values for semen analysis
Volume 2 -6  mL
Sperm concentration 20-250 (106/mL)
Sperm motility > 50 %
Sperm vitality > 50 %
Normal forms > 60 %
If abnormal values for semen analyses are found, and no other cause 
for the abnormalities is obvious, exposures should be eliminated 
using engineering controls and protective equipment, changing the 
patient’s job, or substituting less toxic materials. If removal from 
exposure is used as a diagnostic test, removal should continue as 
long as 18 months before the trial is concluded. (Semen analyses 
should be performed every 2 to 3 months to monitor improvement in 
sperm parameters.) If biomarkers are available to monitor body 
burden of a toxicant, as with lead, the 18-month period should be 
measured from the time the biomarker indicates that the body 
burden of the toxicant has returned to the normal range.
Even if a trial involving removal from exposure has been under­
taken, it is important to remember that infertility may be a problem 
of the couple, rather than due solely to the man or the woman. For 
exam ple, a subm axim al sperm  count in assoc ia tion  w ith  ab­
norm alities of cervical mucus can lead to infertility, when neither 
condition alone would prevent conception. If the fertility evaluation 
suggests that infertility is due to a cumulative effect of the couple 
and the man is exposed to an identified toxicant, a trial of removal 
from exposure may still be appropriate while measures to correct 
the other disorders are carried out.
Occasionally, male infertility is due to both a medical condition and 
an identifiable occupational or environmental cause. The therapeu­
tic approach in these cases should be one that recognizes both 
aspects of the problem. For example, if a varicocele (a condition 
manifested by abnormal dilation of the veins of the spermatic cord, 
which is a frequent cause of oligospermia) coexists with exposure to
11
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lead, elimination of the lead exposure could be tried along with 
consideration of corrective surgery.
Chemical exposures associated with infertility have thus far been 
linked primarily to effects on the male. Potentially comparable effects 
on females have not been elucidated because parameters that 
affect female reproductive capacity cannot be easily measured. 
Chemical exposures should be strictly controlled or eliminated for all 
females of reproductive age. At the very least, pregnant females who 
have had exposures to organic solvents or lead should receive 
ultrasound monitoring and cervical checks if they have engaged in 
strenuous work and are at risk for preterm delivery.
Regulation of Reproductive Hazards
□  Regulatory standards may The most direct approach to reducing environmental or work-related
not be protective of adverse reproductive outcomes is by controlling contamination in
reproductive health. environment and by limiting exposure to toxic substances in the
workplace. Various statutes regulate exposure to reproductive toxi­
cants encountered in the workplace, and a variety of regulatory 
agencies are responsible for enforcing these statutes. No single 
agency has complete regulatory responsibility for reproductive and 
developmental toxicants.
The most comprehensive federal statute governing health and 
safety in the workplace is the Occupational Safety and Health Act of 
1970. The Occupational Safety and Health Administration (OSHA) is 
empowered to promulgate permissible exposure limits (PELs) for 
toxic substances in the workplace, including those posing risks to 
the reproductive health of workers. However, only a handful of the 
thousands of chemicals currently in use are regulated because of 
their potential to produce adverse reproductive effects. Many 
substances that threaten to damage reproduction may do so at 
exposure durations or levels lower than the PELs set to protect 
against other effects.
The Toxic Substances Control Act (TSCA) and the Federal Insecticide, 
Fungicide, and Rodenticide Act (FIFRA) mandate EPA to require the 
testing of products for toxicity and to limit the commercial use of toxic 
substances in the environment and workplace. Regulation of a 
substance under TSCA or FIFRA could theoretically result in a ban of 
the product. Reproductive toxicity, however, has seldom been the 
major consideration in the decision to ban a substance.
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Answering the Questions
Clinicians are frequently questioned about potential risks to the reproductive health of men and women exposed 
to chemical toxicants and about the causes of adverse pregnancy outcomes. These questions most often come 
from persons exposed in the workplace; however, many communities have hazardous substances in air, water, 
and soil. The number of people potentially affected by environmental exposures is relatively large, and these 
persons are probably more susceptible to toxicants than healthy workers. Yet, most references on the medical 
evaluation of adverse pregnancy outcomes or infertility fail to mention the role of environmental toxic exposures.
Clinicians have been given little guidance in answering patients’ questions concerning adverse reproductive and 
developmental outcomes. Most of the information available is from animal studies, and no consensus exists on 
extrapolating from experimental animal data to human risk. Nevertheless, much can be done with the information 
published; reasonable and informed decisions can be made.
The most commonly asked questions regarding the reproductive and developmental effects of exposures are the 
questions in the Pretest on page 1. These questions are answered below in the context of exposure to TCA and 
DCE, as presented in the case study, but additional information is given regarding exposures to other substances 
as well.
a) “Can adverse reproductive effects such as spontaneous abortion and birth defects be caused
by drinking and using contaminated water?”
It is unlikely that the adverse reproductive and developmental effects stated in the case study were caused by 
exposure to TCA or DCE, either by drinking or using contaminated water or by exposures to these substances 
at work. In general, if a link between an adverse reproductive outcome and an environmental exposure is 
strongly suspected and the exposure can be stopped, the parents can be reassured that future pregnancies 
will not be at increased risk. If no clear cause is obvious, but exposure to a potential toxicant exists, the 
management of future pregnancies becomes a concern.
Etiologic questions may be extremely difficult to answer in a legal context. Typically, data are insufficient to link 
specific exposures to specific outcomes. Nevertheless, the same rules used to evaluate any suspected 
environmentally or occupationally caused diseases apply. Other known causes of the abnormality must be 
excluded and the nature, timing, and degree of exposure must be estimated to determine whether the dose 
is comparable to the dose associated with the particular adverse effect.
Parents who have suffered adverse reproductive or developmental outcomes require sensitive counseling 
because they may be concerned about the child’s health, their own health, the presence of undetected genetic 
problems, and risks in future pregnancies. An environmental and occupational history should be obtained, and 
evaluation should proceed as medically indicated. (See Case Studies in Environmental Medicine: Taking an 
Exposure History, ATSDR, 1993.)
b) “I am 3 months pregnant; how will this exposure affect my pregnancy?”
Many substances have been linked to increased rates of spontaneous abortion. TCA and DCE are not among 
these chemicals. If the literature or other sources reveal that an exposure has been associated with an 
increased risk of a birth defect, you can discuss this with the patient in the context of the timing of the exposure 
and background rates of adverse pregnancy outcomes in general. For example, the overall rate of a particular 
severe defect (without exposure) is 1 in 200 births. If a chemical exposure raises the risk of a specific6eiec\ from 
1 in 2000 births to 3 in 2000 births (or 0.3 in 200 births), it would have a relative risk of 3 forthat defect. The overall 
risk of the defect is then increased from 1 per 200 (without exposure) to 1.3 per 200 (with exposure). For many 
people, understanding this relative risk may be reassuring. An increased risk of early fetal loss or of giving birth 
to a small-for-age baby is not an indication for therapeutic abortion.
13
TSDR
However, for some exposures, the risk of adverse outcomes may be considerable. In cases in which the risk 
is high, some persons may choose to terminate the pregnancy. For example, acute exposure to ionizing 
radiation of greater that 30 rads at any stage of gestation is associated with a high probability of congenital 
abnormalities. Another situation in which the relative risk is high is an acute poisoning (e.g., carbon monoxide 
poisoning) that results in severe anoxia of the mother, which can have severe consequences for the fetus.
Ultimately, the decision to maintain or terminate a pregnancy rests with the patient. What is considered a 
significant risk that warrants pregnancy termination depends on a complex set of patient values— individual, 
cultural, and social. It is the responsibility of health professionals to ensure that the patient’s decision is as well 
informed as possible, in terms of both the risks and alternatives. When the relative risks are high, you may wish 
to refer your patient to a genetic counsellor for more help in making this decision.
c) “Is there danger to breast feeding if I have been drinking contaminated water?”
After the child is born, its growth and development can be affected by exposure to substances brought home 
on the clothes of family members or used in the home, and those excreted in breast milk. Obstetricians and 
pediatricians justifiably encourage breast feeding, which provides igA, amino acids, and fats that are 
essential for the developing infant, and considerable psychologic advantages to both mother and child. Only 
in rare cases are the advantages of breast feeding outweighed by the transmission of toxic chemicals.
The dose of the chemical to which a breast-feeding infant is exposed depends on the biologic fate of the 
substance in the mother. Toxicants that are fat soluble may reach high levels in the breast milk, which may 
be the major route of excretion, even though maternal exposure has stopped. By contrast, many organic 
solvents, although fat soluble, are also excreted through the lung, liver, and kidneys, generally decreasing 
maternal body burden soon after exposure has stopped.
The acute health effects resulting from a given infant dose of a substance transmitted in breast milk have been 
defined for only a few substances. Furthermore, chronic effects of low-dose exposures are virtually unknown. 
These uncertainties make the decision of whether to breast feed a difficult one. The following guidelines for 
mercury, PCBs, organic solvents, and lead are based on the limited data available, the considerations outlined 
above, and the availability of a safe alternative.
1. Mercury is the only chemical for which an unequivocal guideline has been set in milk. U.S. Food and 
Drug Administration (FDA) guidelines set a maximum allowable concentration of mercury in over-the- 
counter milk at less than 4 micrograms per liter (|ig/L).
2. Acute effects of PCBs or related halogenated hydrocarbons on the breast-feeding infant are unlikely 
at any maternal blood level. Unless the mother has ingested or otherwise has received a considerable 
dose, breast feeding can be continued in most cases.
3. Maternal exposure to organic solvents should be minimized during breast feeding. Because most 
organic solvents (including TCA) are excreted relatively rapidly, breast feeding can be resumed 
several days after an acute maternal exposure. In the interim, milk can be pumped from the breasts 
(to maintain lactation) and be discarded.
4. The Centers for Disease Control and Prevention (CDC) has set a current action level for blood lead 
in children of 1 o |j.g/deciliter (dL); above this level, adverse health effects have been reported to occur 
in children. A woman who has been exposed to lead should consult her physician and have a 
determination of her blood lead level before breast feeding. (The ratio of the lead concentration in 
maternal blood (or plasma) to the concentration in maternal milk is approximately 1 [Table 4, 
page 10].)
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d) “My wife is having trouble getting pregnant; could a chemical exposure that I am receiving be 
responsible?”
A couple is defined as infertile when conception has not been achieved after 1 year of unprotected sexual 
intercourse. Approximately 10% of all couples are infertile. Male factors are estimated to account for about 40% 
of this infertility, failure of ovulation for 1 o% to 15%, tubal factors for up to 30%, and cervical factors for about 
5%. In approximately 10% to 20% of infertility cases, the cause is not identified.
Infertility associated with chemical exposures has thus far been linked primarily to effects on the male. This 
may be partially because semen can be measured and analyzed and thus provides a ready means of 
assessing reproductive health in men exposed to potential toxicants. No similar parameter is available to 
determine female reproductive health after chemical exposure. Changes in menstrual patterns may be a 
biomarker for chemically induced oocyte toxicity and are currently being investigated.
To demonstrate that male infertility is caused by a chemical exposure, the following four criteria must be met:
1. The results of at least two semen analyses must be abnormal (e.g., sperm must be inadequate in 
number or have abnormal morphology, poor motility, or decreased ability to penetrate the egg).
2. Other causes of infertility must be excluded. An abnormal semen analysis does not necessarily 
implicate a toxicant as a causative agent. Major causes of male infertility are primary endocrinopathy, 
prior testicular injury, testicular surgery, mumps, gonadotoxic drugs (e.g., chemotherapy with 
cytotoxic drugs or estrogens), varicocele, urologic abnormalities (e.g., retrograde ejaculation), 
ductal obstruction, venereal disease, or vasectomy. These may not cause infertility in all men who 
are affected by them.
3. Exposure to a toxicant known or suspected of causing infertility must have occurred. Table 2, 
page 7, lists substances that are known or suspected to cause male infertility in humans or have 
positive study results in experimental animals. Many agents have not been adequately studied, 
so clinicians should keep an open mind if the first two criteria have been met and if exposure 
involves an agent that chemically or structurally resembles an identified reproductive toxicant.
4. Because effects on spermatogenesis are usually reversible, a fourth diagnostic criterion is 
improvement after removal from exposure. A clear improvement after exposure ceases is 
compelling diagnostic evidence and may be especially helpful when data about the toxicant in 
question are limited. However, failure to improve does not demonstrate conclusively that 
exposure is not the cause because some toxicants affect the spermatogonial stem cells causing 
long-term or permanent infertility.
e) “We are planning to become pregnant; is it safe to do so?”
Answering this question for patients entails the following three steps:
• Reviewing the information on the exposure (e.g., agent, timing, dose)
• Reviewing the known effects of the exposure and the doses at which effects have been
reported to occur
• Applying clinical judgment, taking the individual patient into account
Although current data do not permit a rigid or scientific consensus on guidelines, the following general 
paradigm is proposed:
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1. If the exposure occurs in the home or community environment setting and it is demonstrated 
that the patient is exposed at doses that cause significant risk, immediate exposure reduction, 
perhaps even relocation, is required. If the exposure occurs in the occupational setting, 
decreasing exposure through engineering controls, materials substitution, or job transfer is 
recommended.
2. Rigorous control of exposure is necessary if significant risk is suspected. (A combination of 
experimental animal and human data is used to determine if a risk is suspected.)
3. If only minimal exposure to established or suspected agents occurs, simple modifications of the 
home, community, or workplace environments to reduce or eliminate contact may be feasible.
Suggesting a job transfer can raise difficult social and economic issues. Some employers have a policy 
regarding transfer during pregnancy, and many will follow the recommendation of a physician regarding job 
relocation. However, an employer usually is not required to transfer a pregnant worker to a safe job (see 
Suggested Reading List, page 17).
The difference in emphasis between the answers to this question and (b) above is important. The answer to
(b) considers medical treatment that has potential morbidity and mortality implications forthe patient, whereas 
this answer affords the opportunity to practice prevention. Preventive actions are more desirable and often 
require less certainty than other interventions.
f) “What is an ATSDR health consultation? What is an ATSDR public health assessment?”
A health consultation is ATSDR's response to a question or request for information pertaining to a hazardous 
substance or site. The procedure provides advice on specific public health issues that arise from actual or 
potential exposure to a hazardous substance. When a rapid response is required, a health consultation is 
a more limited method of addressing concern about potential adverse health effects than is an ATSDR 
public health assessment.
A public health assessment is a formal evaluation of relevant environmental data, health outcome data, and 
community concerns associated with a site where a hazardous substance has been released. In the process 
of assessing the current or future impact of a release on public health, studies or actions needed to evaluate, 
mitigate, or prevent human health effects are defined. Written health advisories or other recommendations 
may be developed and issued.
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Many of the issues in the series Case Studies in Environmental Medicine concern individual chemicals; each 
contains information on the reproductive and developmental effects of that chemical. Members of the 
Organization of Teratology Information Services (OTIS) and of the Association of Occupational and Environ­
mental Clinics (AOEC) are listed by state in Appendices I and II, respectively.
In addition, risklines (telephone hotlines) or clinics that address reproductive and developmental hazards are 
available in the United States and Canada. Many of the following organizational resources are listed in 
Reproductive Hazards in the Workplace: A Syllabus for Cinicians, by M. Paul and S. Kurtz, University of 
Massachusetts, 1990.
Arizona
Arizona Teratogen Information Service. Arizona Health Sciences Center, Tucson, AZ. Serves Arizona only: 
(602) 626-6016 or (800) 362-0101 (Arizona only)
California
Hazards Evaluation System and Information Service (HESIS), California Department of Health Services, 
Berkeley, CA. Serves California only: (510) 540-3014 (collect calls accepted from within California)
Connecticut
Connecticut Pregnancy Exposure Riskline, University of Connecticut Health Center, Farmington, CT. Serves 
Connecticut only: (203) 674-1465 or(soo) 325-5391 (Connecticut only)
Colorado, Montana, Nevada, and Wyoming
Rocky Mountain Poison and Drug Center and the University of Colorado Genetics Unit, Denver, CO. Serves 
primarily Colorado, Montana, Nevada, and Wyoming: (800) 332-3073 (Colorado only), (800) 525-5042 (Montana 
only), (800) 446-6179 (Nevada only), (800) 442-2702 (Wyoming only). Out of state: (303) 629-1123; physicians 
only: (303) 270-8742
Florida
Teratogen Information Service, University of Florida, Gainsville, FL. Serves Florida only: (904) 392-4104 
Illinois
Illinois Teratogen Information Service, Illinois Department of Public Health, Chicago, IL. Serves Illinois only: 
(312) 903-7441 or (800) 252-4847
Massachusetts
Occupational and Environmental Reproductive Hazards Center, University of Massachusetts Medical Center, 
Worcester, MA. Provides clinical consultation and health provider education regarding reproductive azards: 
(508) 856-6162.
Teratogen Information Service, Franciscan Children’s Hospital, Boston, MA. Serves primarily Massachusetts 
but will accept calls from practitioners nationwide: (617) 787-4957 or (800) 322-5014 (Massachusetts only)
18
Reproductive and Developmental Hazards
Nebraska
Nebraska Teratogen Project, University of Nebraska Medical Center, Omaha, NB. Serves primarily Nebraska 
but will accept calls from practitioners in surrounding states: (402) 266-2900
New Jersey
Teratogen Information Network, University of Medicine and Dentistry of New Jersey. Serves primarily New 
Jersey: (609) 757-7812 or (800) 441 -0025 (New Jersey only)
Pennsylvania
Pregnancy Healthline, Pennsylvania Hospital, Philadelphia, PA. Serves primarily Pennsylvania: (215) 829-KIDS 
(829-5437)
Utah
Pregnancy Riskline, Utah Department of Health and University of Utah, Salt Lake City, UT. Serves Montana, 
Nevada, and Utah: (800) 521-2229 (Montana and Nevada only); (801) 583-2229 or (800) 822-2229 (Utah only)
Vermont
Vermont Pregnancy Risk Information Service, University of Vermont, Burlington, VT. Serves Vermont only: 
(802) 658-4310 or (800) 531-9800 (Vermont only)
Washington
Seattle Poison Center, Children’s Hospital and Medical Center, Seattle, WA. Serves Washington only: (206) 
526-2121 or (800) 732-6985 (Washington only)
Canada
A team of physicians and information specialists in the MotherRisk Program at the Hospital for Sick Children, 
Toronto, Ontario, ([416] 813-6780) will counsel a caller about the safety of an exposure to drugs, chemicals, 
or radiation during pregnancy or breast feeding. Please be prepared to provide them with the specific name 
of the product about which you are concerned and the exact dates of the exposure. They will not suggest or 
prescribe medication by telephone and will not answer questions about advanced maternal age, amnio­
centesis, chorionic villae sampling, or other pregnancy-related tests. Questions concerning a genetic 
condition should be directed to the Department of Clinical Genetics at the Hospital for Sick Children 
([416] 813-6390).
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Computer Databases
Computer databases dedicated to reproductive and developmental hazards
REPROTOX
Contact: Greta Ober
Reproductive Toxicology Center
Columbia Hospital for Women Medical Center
2425 L Street, NW
Washington, DC 20037
(202) 293-5137
TERIS
Contact: Janine E. Polifka, Ph.D.
Teratogen Information System (includes Shepard’s Catalog o f Teratogenic Agents) 
Department of Pediatrics, TRIS WJ-10 
University of Washington 
Seattle, WA 98195
REPRORISK
Contact: Betty Dabney, Ph.D.
Micromedex, Inc.
600 Grant Street 
Denver, CO 80203-3527 
(303) 831-1400
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APPENDIX I
Organization of Teratology Information Services (OTIS)
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ARIZONA
Tucson
Arizona Teratogen Information Program (ATIP)
University of Arizona/Department of Pediatrics 
Section of Genetics/Dysmorphology 
2504 East Elm Street 
Tucson, AZ 85716
(602) 795-5675 or in AZ (800) 362-0101 FAX (602) 626-4884 
Contacts: Dee Quinn, MS; H. Eugene Hoyme, MD; Lynn Hauck, MS
CALIFORNIA
San Diego
California Teratogen Information Service & Clinical Research Program
University of California, San Diego
Department of Pediatrics
Division of Dysmorphology & Teratology
225 Dickinson Street #8446
San Diego, CA 92103-8446
(619) 294-6084, (800) 532-3749 (CA only), (619) 294-6217 (administrative only) FAX (619) 291 -0946 
Contacts: Kenneth Loyns Jones, MD; Kathleen Johnson; Christina Chambers; Lyn Dick; Robert Felix
COLORADO
Denver
TIES
The Children's Hospital 
B300 Genetics 
1056 East 19th Avenue 
Denver, CO 80218
(303) 861-6395, (800) 332-2082 (CO only), (800) 525-4871 (Wyoming only) FAX 303-861-3992 
Contacts: Karen Prescott, MS; David Manchester, MD; Carol Walton, MS; Cathy Marquez
CONNECTICUT
Farmington
Connecticut Pregnancy Exposure Information Service 
Division of Human Genetics Rm L-5072 
University of Connecticut Health Center 
263 Farmington Avenue 
Farmington, CT 06030
(203)679-1502, (800)325-5391 (CTonly) FAX (203) 679-1531
Contacts: Glenda Lee Spivey, MS; Sally S. Rosengren, MD; Sharon Voyer, MS; Robert Pilarski, MS; Joanne Brochu
DISTRICT OF COLUMBIA
Washington, DC
Reproductive Toxicology Center 
2440 M Street NW, Suite 217 
Washington, DC 20037-1404
(202) 293-5137 FAX (202) 293-7256
Contacts: Anthony R. Scialli, MD; Armand Lione, PhD; G. Kay Padgett; Christine Colie, MD; Greta D. Ober
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FLORIDA
Gainesville
Teratogen Information Service 
University of Florida Health Science Center 
Box 100296
Gainesville, FL 32610-0296
(904) 392-3050 FAX (904) 392-3051
Contacts: Donna H. Poynor, MM; Charles A Williams, MD
Miami
Florida Teratogen Information Service 
University of Miami School of Medicine 
Mailman Center PO Box 016820 
Miami, FL 33101
(305) 547-6464 FAX (305) 547-3919 
Contact: Virginia H. Carver, PhD
Tampa
Teratogen Information Service 
University of South Florida 
Department of Pediatrics, Box 15-G 
12901 Bruce B Downs Boulevard 
Tampa, FL 33613
(813)974-2262 FAX (813) 974-4985
Contacts: James K. Hartsfield, DMD; Boris G. Kousseff, MD; Suzanne R. Sage, RN, MS; 
Jaime L. Frias, MD
GEORGIA
Atlanta
Centers for Disease Control and Prevention 
Division of Birth Defects and Genetic Diseases 
Mail Stop F45 
1600 Clifton Road 
Atlanta, GA 30333
(404) 488-4967 FAX (404) 488-4643
Contacts: Muin J. Khoury, MD, PhD; José F. Cordero, MD, MPH
ILLINOIS
Chicago
Illinois Teratogen Information Service 
Northwestern University 
333 East Superior, Suite 1543 
Chicago, IL 60611
(312) 908-7441, (800) 252-4847 FAX (312) 908-6643 
Contacts: Eugene Pergament, MD, PhD; Amy Risman, MS
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INDIANA
Indianapolis
Indiana Teratogen Information Service 
Department of Medical Genetics 
Indiana University Medical Center 
975 West Walnut Street 
Indianapolis, IN 46202 
(317) 274-1071 FAX (317) 274-2387
Contacts: David D. Weaver, MD; Peg Davee, MS; Lola Cook, MS
IOWA
Iowa City
University of Iowa Prenatal Diagnostic Unit
Department of Obstetrics and Gynecology
University of Iowa
Iowa City, IA 52241
(319) 356-3561 FAX (319) 355-6728
Contacts: Roger Williamson, MD; Katharine Wenstrom, MD; Susan Sipes, MD; Stanley Grant, RN
University of Iowa Teratogen Information Service
Department of Pediatrics/Medical Genetics
University of Iowa Hospitals & Clinics
Iowa City, IA 52242
(319) 356-2674 FAX (319) 356-3347
Contacts: James W. Hanson, MD; Ann Muilenburg, RN, MA
KANSAS
Wichita
Prenatal Diagnostic & Genetic Clinic 
HCA Wesley Medical Center 
550 North Hillside 
Wichita, KS 67214 
(316) 688-2362
Contacts: Sechin Cho, MD; Paula Floyd, RN, MN; Richard Lutz, MD; Nancy McMaster, RN, MEd
MASSACHUSETTS
Boston
Massachusetts Teratogen Information Service (MTIS)
National Birth Defects Center 
30 Warren Street 
Boston, MA 02135
(617) 787-4957, (800) 322-5014 (MAonly), (617) 787-5834 (office) FAX (617) 787-6936
Contacts: Susan Rosenwasser, MEd; Jane O’Brien, MD; Katryn Miller, MEd; Robin Maltz, MPH; Karen Treat, MS
Embryology Teratology Unit 
Warren 801
Massachusetts General Hospital 
Fruit Street 
Boston, MA 02114
(617)726-1742 FAX (617) 726-1866
Contacts: Lewis B. Holmes, MD; Ailish M. Hayes, MD; Gerald V. Raymond, MD; Joan M. Stoler, MD
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MASSACHUSETTS (continued)
Boston (continued)
TERAS
c/o Dr. Fred Bieber 
Department of Pathology 
Brigham & Women’s Hospital 
75 Francis Street 
Boston, MA 02115
(617)732-6507 FAX (617) 732-7513
Contacts: Frederick R. Bieber, PhD; David Genest; George Mutter; Drucilla Roberts; Christopher Crum 
Worcester
Occupational and Environmental Reproductive Hazards Center
University of Massachusetts Medical Center
Department of Obstetrics and Gynecology
55 Lake Avenue North
Worcester, MA 01655
(508) 856-6162 FAX (508) 856-2965
Contacts: Maureen Paul, MD, MPH; Jay Himmelstein, MD, MPH; Sabrina Kurtz, MEd; Carol Lewis; 
Gregory Garran
MISSOURI
Columbia
Columbia Teratogen Information Service
Department of Child Health
Medical Genetics Division
University of Missouri
1 Hospital Drive
Columbia, MO 65212
(314)882-6991 FAX (314) 882-2742
Contacts: Virginia Proud, MD; Judith Miles, MD; Kathy Morris, MSSW 
St. Louis
Genetics and Environmental Information Service (GENIS)
Washington University School of Medicine 
Department of Obstetrics, Gynecology, Genetics 
216 South Kingshighway 
St. Louis, MO 63110
(314)454-8172 FAX (314) 454-7358
Contacts: Heidi Beaver, MPH; Sheri Babb; Laura Turlington, MS; Cindy Johnson, MS;
James P. Crane, MD; Jeffrey M. Dicke; Jane E. Corteville; Diana L. Gray
NEBRASKA
Omaha
Nebraska Teratogen Project
University of Nebraska Medical Center
600 South 42nd Street
Omaha, NE 68198-5430
(402) 559-5071 FAX (402) 559-5737
Contacts: Beth Conover, RN, MS; Bruce Buehler, MD
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Camden
New Jersey Pregnancy Risk Information Service 
UMDNJ-Robert Wood Johnson Medical School 
401 Haddon Avenue 
Camden, NJ 08103
(609) 757-7812, (800) 441-0025 (NJ only) FAX (609) 757-9792
Contacts: Michael K. McCormack, PhD; Carol Zuber, MS; Charlotte Furey, BSN
N EW  YO R K  
Rochester
Perinatal Environmental and Drug Consultation Service (PEDECS)
Department of Obstetrics and Gynecology, PO Box 668
University of Rochester Medical Center
601 Elmwood Avenue
Rochester, NY 14642
(716) 275-3638 FAX (716) 244-2209
Contact: Richard K. Miller, PhD
West Seneca
Teratogen Information Service
1200 East and West Road, Building 16 
West Seneca, NY 14224 
(716) 674-6300 x4812
Contacts: Luther K. Robinson, MD; Sandra Gangell
NORTH DAKOTA 
Grand Forks
Division of Medical Genetics, Department of Pediatrics
University of North Dakota School of Medicine
501 Columbia Road
Grand Forks, ND 58203
(701)777-4277 FAX (701) 777-3894
Contacts: John T. Martsolf, MD; Mary Ebertowski, RN
P E N N S Y LV A N IA
Philadelphia
Pregnancy Healthline 
Pennsylvania Hospital 
8th and Spruce Streets, 7th floor 
Philadelphia, PA 19107
(215)829-3601 FAX (215) 829-7423
Contacts: Betsy Schick-Boschetto, MSN; Alan E. Donnenfeld, MD; Ronald J. Librizzi, DO
Pittsburgh
Pregnancy Safety Hotline 
Department of Reproductive Genetics 
School of Nursing, 2nd Floor 
Western Pennsylvania Hospital 
4800 Friendship Avenue 
Pittsburgh, PA 15224 
(412) 687-SAFE FAX (412) 578-1125
Contacts: Michael J. Kerr, MS; Kathy A. Bournikos, MS; Karen Filkins, MD; Christann Jackson, MD; 
Elizabeth Gettig
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PENNSYLVANIA (continued)
Pittsburgh
Department of Reproductive Genetics 
Magee-Women’s Hospital 
300 Halket Street 
Pittsburgh, PA 15213 
(412)647-4168 FAX (412) 647-4343
Contacts: Sandra G. Marchese, MS; Mona Penles Stadler, MS; Deanna P. Stelle, MS; Luanne Fraer, MS; 
Amy Niklaus, MS; Faith Callif-Daley, MS; Dolores Pegram, MEd
SOUTH DAKOTA 
Vermillion
Teratogen and Birth Defects Information Project
School of Medicine
University of South Dakota
414 East Clark
Vermillion, SD 57069
(800)962-1642 FAX (605) 677-5124
Contacts: Virginia P. Johnson, MD; Patricia Skorey, MNS, BSN; Carol Strom, MS
TEXAS
Denton
Genetic Screening and Counseling Service
PO Box 2467
Denton, TX 76202-2467
(817) 383-3561 FAX (817) 382-6235
Contacts: Lori Wolfe, MD; Becky Althaus, MS; Donald W. Day, MD; Margaret Drummond-Borg, MD; 
Judith Martin, MD
UTAH
Salt Lake City
Pregnancy Riskline 
44 Medical Drive 
Salt Lake City, UT 84113
(801) 583-2229 FAX (801) 584-8488
Contacts: John Carey, MD; Marcia Feldkamp; Lynn Martinez; Marsha Leen-Mitchell
VERMONT
Burlington
Vermont Pregnancy Risk Information Service 
Vermont Regional Genetics Center 
1 Mill Street, Suite 3-1 
Burlington, VT 05401
(802) 658-4310
Contacts: Alan E. Guttmacher, MD; Wendy C. McKinnon, MS
WASHINGTON
Seattle
Central Laboratory for Human Embryology
Department of Pediatrics RD-20, School of Medicine
University of Washington
Seattle, WA 98195
(206)543-3373 FAX (206) 543-3184
Contacts: Tom Shepard, MD; Alan Fantel, MD; Phil Mirkes
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LaCrosse
Teratogen Information Service 
LaCrosse Regional Genetic Services 
PO Box 1326 
LaCrosse, Wl 54602
(608) 791-6681, (800) 362-9567 (Wl, MN, IA, northern IL)
Contact: Janet Williams, MS
Madison
Wisconsin Teratogen Project 
Waisman Center Room 347 
1500 Highland Avenue 
Madison, Wl 53705
(608) 262-4719, (800) 442-6692 FAX (608) 263-3496
Contacts: Renata Laxova, MD; Joanne Haun, MS; Catherine Reiser, MD
Milwaukee
Great Lakes Genetics
2323 North Mayfair Road, Suite 410
Milwaukee, Wl 53226
(414) 475-7400, (414) 475-7223
Contacts: Lois Magnuson, RN; Jurgen Herrmann, MD; Bonnie-Jo Bates, MD
Eastern Wisconsin Teratogen Service 
Medical Genetics Institute, SC 
4555 West Schroeder Drive, Suite 180 
Milwaukee, Wl 53223
(414) 357-6555 FAX (414) 357-9394
Contacts: B. Rafael Elejalde, MD; Maria M. de Elejalde, MS, RN
28
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APPENDIX II
Association of Environmental and Occupational Clinics (AEOC)
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San Francisco
Judie Guerriero, RN, MPH
Occupational Health Clinic
San Francisco General Hospital
1001 Potrero Avenue, Building 9, Room 109
San Francisco, CA 94110
(415) 206-5391 FAX (415) 206-8949
Alt. Contact: Patricia Quinlan, MPH
Robert Harrison, MD
Occupational & Environmental Medicine Clinic
University of California at San Francisco
400 Parnassus Avenue A585
San Francisco, CA 94143
(415) 476-1841 FAX (415) 476-6426
C O LO R A D O
Denver
Kathleen Kreiss, MD
National Jewish Center of Immunology and Respiratory 
Medicine 
1400 Jackson Street 
Denver, CO 80206
(303) 398-1520 FAX (303) 398-1452 
Alt. Contacts: Cecile Rose, MD; Peggy Mroz, MSPH
C O N N E C T IC U T  
New Haven
Mark Cullen, MD
Yale Occupational/Environmental Medicine Program
333 Cedar Street
New Haven, CT 06510
(203) 785-5885 FAX (203) 785-7391
Farmington
Eileen Storey, MD, MPH 
University of Connecticut Occupational Medicine 
Program 
263 Framington Avenue 
Farmington, CT 06030
(203) 679-2366
Alt. Contact: Michael Hodgson, MD
WASHINGTON, D.C.
Laura Welch, MD
Division of Occupational and Environmental Medicine
School of Medicine, George Washington University
2300 K Street, NW
Washington, DC 20037
(202) 994-1734 FAX (202) 994-0247
Alt. Contact: Rosemary Sokas, MD
30
Reproductive and Developmental Hazards
G E O R G IA
Atlanta
Howard Frumkin, MD, MPH
Division of Environmental and Occupational Health
Emory University School of Public Health
1599 Clifton Road, NE
Atlanta, GA 30329
(404) 727-3697 FAX (404) 727-8744
ILL IN O IS
Bridgeview
Geralynn Kahn, MD, MPH
MacNeal Occupational Medicine Clinic at Bridgeview Medical Center
7217 N 84th Street
Bridgeview, IL 60455
(708) 795-3400 FAX (708) 795-3341
Alt. Contact: Linda Cocchiarella, MD, MS
Chicago
Stephen Hessl, MD, MPH
Occupational Medicine Clinic
Cook County Hospital
720 South Wolcott
Chicago, IL 60612
(312) 633-5310 FAX (312) 633-6442
Alt. Contact: Ann Naughton, RN
Penny Higgins, RN, BS
Managed Care Occupational Health Program
Mount Sinai Hospital Medical Center
2720 West 15th Street
Kling Building Room 534
Chicago, IL 60608
(312) 650-6480 FAX (312) 650-6213
Alt. Contact: Peter Orris, MD
Linda Forst, MD, MS, MPH
University of Illinois Occupational Medicine Program
840 S. Wood M/C 678, P.O. Box 6998
Chicago, IL 60612
(312) 996-2592 FAX (312) 413-0122
Alt. Contact: Stephen Hessl, MD, MPH
IO W A  
Iowa City
David Schwartz, MD
University of Iowa, Occupational Medicine Clinic 
Department of Internal Medicine, College of Medicine 
T304, GH
Iowa City, IA 52242
(319) 356-8269 FAX (319) 356-8608
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Lexington
Arthur Frank, MD
University of Kentucky Occupational Medicine Program
Warren Wright Medical Plaza
800 Rose Street
Lexington, KY 40536-0084
(606) 257-5166 FAX (606) 258-1038
Alt. Contacts: David Fahringer, PA-C;
Terence R. Collins, MD, MPH
LO U IS IA N A  
New Orleans
Peter G. Casten, MD, MPH
Ochsner Center for Occupational Health
1514 Jefferson Highway
New Orleans, LA 70121
(504) 838-3955 Fax (504) 838-5721
Alt. Contacts: Douglas A. Swift, MD, MPH;
Todd W. McCune, MD, MPH
M A R YLA N D
Baltimore
Eric Schaub, MD, MS 
Johns Hopkins University
Center of Occupational and Environmental Health
5501 Hopkins Bayview Circle
Baltimore, MD 21224
(410) 550-2322 FAX (410) 550-2090
Alt. Contact: Theresa Pluth, MSN, MPH
James Keogh, MD
Occupational Health Project/School of Medicine
Division of General Internal Medicine
University of Maryland
405 Redwood Street
Baltimore, MD 21202
(410) 328-7464 FAX (410) 328-8326
M A S S A C H U S E TTS
Boston
Christine Oliver, MD, MPH, MS 
Massachusetts General Hospital 
Occupational Medicine Clinic 
32 Fruit Street 
Boston, MA 02114 
(617) 726-2721 or (617) 726-2741 
Alt. Contacts: Elisha Atkins, MD;
Dean Hashimoto, MD, JD; Bruce Shackleton, EdD
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Cambridge
Rose Goldman, MD, MPH
Occupational and Environmental Health Center
Cambridge Hospital
1493 Cambridge Street
Cambridge, MA 02139
(617) 498-1580 FAX (617) 498-1671
Alt. Contact: Cathy Schwartz, RN
South Braintree
Dianne Plantamura, Coordinator
Center for Occupational and Environmental Medicine
Massachusetts Respiratory Hospital
2001 Washington Street
South Braintree, MA 02184
(617) 848-2600 FAX (617) 849-3290
Alt. Contact: David Christiani, MD, MPH, Director
Worcester
Glenn Pransky, MD, MOH
Occupational Health Service
Department of Family and Community Medicine
University of Massachusetts
55 Lake Avenue North
Worcester, MA 01655
(508)856-2734 Fax (508) 856-1212
Alt. Contacts: Charles Sweet, MD, MPH;
Kathleen Rest, PhD, MPA
M IC H IG A N  
Ann Arbor
David Garabrant, MD
Occupational Health Program
School of Public Health, University of Michigan
1420 Washington Heights
Ann Arbor, Ml 48109-2029
(313) 764-2594 FAX (313) 763-8095
Alt. Contacts: Alfred Franzblau, MD; Tom Robins, MD
Detroit
Ray Demers, MD, MPH
Division of Occupational Health
Wayne State/Department of Family Medicine
4201 St. Antoine, Suite 4-J
Detroit, Ml 48201
(313) 577-1420 FAX (313) 577-3070 
Alt. Contacts: Mark Upfal, MD, MPH;
James Blessman, MD, MPH;
Maryjean Schenk, MD, MPH;
Kendra Schwartz, MD, MPH
East Lansing
Kenneth Rosenman, MD 
Michigan State University 
Department of Medicine 
B338 Clinical Center 
East Lansing, Ml 48824-1317
(517) 353-1846 FAX (517) 336-2759
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Southfield
Margaret Green, MD, MPH
Center for Occupational and Environmental Medicine 
15901 West Nine Mile Road, Suite 410 
Southfield, Ml 48075
(313) 559-6663 FAX (313) 559-8254 
Alt. Contact: Michael Harbut, MD, MPH
M IN N E S O TA
St. Paul
Paula Geiger, Administrative Secretary 
Ramsey Clinic
Occupational and Environmental Health and Occupational Medicine Residency Training Program
640 Jackson Street
St. Paul, MN 55101-2595
(612) 221-3771 FAX (612) 221-3874
Alt. Contact: William H. Lohman, MD
N EW  JE R S E Y  
Piscataway
Howard Kipen, MD, MPH
Environmental and Occupational Health Clinical Center 
Environmental and Occupational Health Sciences 
Institute
UMDNJ-Robert Wood Johnson Medical School
P.O. Box 1179
Piscataway, NJ 08855-1179
(908) 932-0182 FAX (908) 932-0127
Alt. Contact: Gail Buckler, RN, MPH, COHN
N EW  YO R K  
Latham
Anne Tencza, RN, COHN
Eastern New York Occupational Health Program
1201 Troy Schenectady Road
Latham, NY 12110
(518) 783-1518 FAX (518) 783-1827
Alt. Contact: David L. Orgel, MD, MPH
New York
Stephen Mooser, MPH 
Mount Sinai
Irving J. Selikoff Occupational Health Clinical Center
P.O. Box 1057/1058 Gustave Levy Place
New York, NY 10029
(212) 241-6173 FAX (212) 996-0407
Alt. Contacts: Stephen Levin, MD; Robin Herbert, MD
George Friedman-Jimenze, MD
Bellvue Occupational and Environmental Health Clinic
Bellvue Hospital, Room CD349
27th Street & First Avenue
New York, NY 10016
(212) 561-4572 FAX (212) 561-4574
Alt. Contact: Millicent Friedman, MPH
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Stony Brook
Wajdy Hailoo, MD
Stony Brook Occupational Medicine Center 
HSC, L 3-086
State University of New York
Stony Brook, NY 11794
(516) 444-2167 FAX (516) 444-7525
Syracuse
Michael B. Lax, MD, MPH
Central New York Occupational Health Clinic Center
550 Harrison Center, Suite 300
Syracuse, NY 13202
(315) 464-6422 FAX (315) 464-7510
N O R TH  C A R O LIN A  
Durham
Dennis J. Darcey, MD, MSPH
Duke University Medical Center
Division of Occupational and Environmental Medicine
Box 2914
Durham, NC 27710 
(919)286-3232 FAX (919) 286-1021 
Alt. Contact: Gary Greenberg, MD, MPH
O H IO
Cincinnati
James Lockey, MD, MS
Center for Occupational Health
University of Cincinnati College of Medicine
Eden and Bethesda Avenue
Cincinnati, OH 45267-0187
(513) 558-1234 FAX (513) 558-1010
Alt. Contacts: Douglas Linz, MD, MS;
Susan Pinney, PhD
Harriet Applegate
Greater Cincinnati Occupational Health Center
Jewish Hospital Evandale
10475 Reading Road, Suite 405
Cincinnati, OH 45241
(513) 769-0561 FAX (513) 769-0766
Alt. Contact: Margaret Atterbury, MD, MPH
Cleveland
Seth Foldy, MD
Occupational/Environmental Health Clinic
Department of Family Medicine
MetroHealth Medical Center
2500 MetroHealth Drive
Cleveland, OH 44109-1998
(216) 459-5737 FAX (216) 459-3297
Alt. Contact: Kathleen Fagan, MD
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Oklahoma City
Lynn Mitchell, MD
University Occupational Health Services 
Oklahoma Memorial Hospital 
800 NE 13th Street, Room 5E 109 
Oklahoma City, OK 73104
(405) 271-3100 FAX (405) 271-4125 
Alt. Contact: Roy DeHart, MD, MPH
P E N N S Y LV A N IA
Philadelphia
Eddy Bresnitz, MD, MS
Division of Occupational and Environmental Health
Medical College of Pennsylvania
3300 Henry Avenue
Philadelphia, PA 19129
(215) 842-6540 FAX (215) 843-2448
Alt. Contacts: Harriett Rubenstein, JD, MPH;
Jessica Herstein, MD, MS
Pittsburgh
David Tollerud, MD, MPH
Occupational and Environmental Medicine Program
University of Pittsburgh
130 DeSoto Street, Room A729
Pittsburgh, PA 15261
R H O D E ISLA N D  
Pawtuckett
David G. Kern, MD, MOH 
Memorial Hospital of Rhode Island 
Occupational Health Service
Brown University Program in Occupational Medicine 
111 Brewster Street 
Pawtuckett, Rl 02860 
(401)729-2859 FAX (401) 722-0198
W A S H IN G TO N
Seattle
Linda Rosenstock, MD
Occupational Medicine Program
University of Washington Harborview Medical Center
325 9th Avenue ZA-66
Seattle, WA 98104
(206) 223-3005 FAX (206) 223-8247
Alt. Contacts: Scott Barnhart, MD;
Matt Keifer, MD
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WEST VIRGINIA 
Huntington
Chris McGuffin, MS
Division of Occupational and Environmental Health
Department of Family and Community Medicine
Marshal University School of Medicine
1801 6th Avenue
Huntington, WV 25755
(304) 696-7045 FAX (304) 696-7048
Alt. Contact: Karen Mulloy, DO, MSCH
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Posttest and Credits
Continuing education credit is available to health professionals who use this monograph and complete the 
posttest. The criterion for awarding continuing medical education (CME) credits and continuing education units 
(CEU) is a posttest score of 70% or better.
The Centers for Disease Control and Prevention (CDC) is accredited by the Accreditation Council for Continuing 
Medical Education (ACCME) to sponsor continuing medical education for physicians, and by the International 
Association for Continuing Education and Training (IACET) to sponsor continuing education units for other health 
professionals.
The Agency for Toxic Substances and Disease Registry, in joint sponsorship with CDC, is offering 1 hour of CME 
credit in category 1 of the Physician's Recognition Award of the American Medical Association and CEU for other 
health professionals upon completion of this monograph.
In addition, the series Case Studies in Environmental Medicine has been reviewed and is acceptable for credit 
by the following organizations:
The American Academy of Family Physicians (AAFP). This program has been reviewed and is acceptable for 
1 prescribed hour by the American Academy of Family Physicians (term of approval: beginning January 1992). 
For specific information, please consult the AAFP Office of Continuing Medical Education.
The American College of Emergency Physicians (ACEP). Approved by the American College of Emergency 
Physicians for 1 hour per issue of ACEP Category I credit.
The American Osteopathic Association (AOA). AOA has approved this issue for 1 credit hour of Category 
2-B credit.
The American Association of Occupational Heath Nurses (AAOHN). AAOHN has approved this program for 
1.0 contact hours. Applicant will receive the assigned code number in the award letter.
The American Board of Industrial Hygiene (ABIH). ABIH has approved this program for 0.5 certification 
maintenance (CM) point per 3 case studies. The CM approval number is 2817.
To receive continuing education credit (CME or CEU), complete the Posttest on page 40 in the manner shown in 
the sample question below. Circle all correct answers.
Which of the following is known to precipitate migraine headaches?
After you have finished the Posttest, please record your answers on the answer sheet on the inside back cover 
and complete the evaluation on the lower half of that page. Fold, staple, and mail the back cover to Continuing 
Education Coordinator, Agency for Toxic Substances and Disease Registry, Division of Health Education, E33, 
1600 Clifton Road, NE, Atlanta, GA 30333. Your confidential test score will be returned with an indication of where 
the correct answers can be found in the text. Validation of earned CME credit and CEU will also be forwarded to 
participants, and their names, if requested, will be placed on the mailing list to receive other issues in the Case 
Studies in Environmental Medicine series.
»fatigue
alcohol
c. grapefruit 
(c£)sunlight 
e. sleep
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* POSTTEST: REPRODUCTIVE and DEVELOPMENTAL HAZARDS
Circle all correct answers and transfer your answers to page 41.
1. Which of the following statements is (are) true?
a. If an exposure is hazardous to the fetus, the mother will also be ill from the exposure.
b. In the occupational setting, most exposures to the fetus occur by the mother inhaling hazardous chemicals.
c. Chemical exposures that occur before, during, or after conception can harm the developing fetus.
d. Substances at work and in the environment can affect male fertility.
e. No studies have documented an association between workplace exposures and ooctye damage or loss.
2. Which of the following substances are excreted in breast milk?
a. lead
b. fiberglass
c. ammonia
d. mercury
e. polychlorinated biphenyls (PCBs)
3. Which of the following compounds have been strongly associated with infertility in exposed men?
a. 1,2-dibromo-3-chloropropane (DBCP)
b. lead
c. benzene
d. cadmium
e. ionizing radiation
4. Which of the following has been strongly associated with spontaneous abortion in exposed women?
a. lead
b. 2,4-dichlorophenoxyacetic acid (2,4-D, a component of Agent Orange)
c. video display terminals
d. anesthetic gases
e. carbon disulfide
5. Which of the following statements is (are) true?
a. To be considered a reproductive hazard, a chemical agent must act prior to conception.
b. All reproductive and developmental toxicants damage the genetic material in the ovum or sperm.
c. Risk factors for male fertility need not be considered in the workplace.
d. A compound stored in bone or fat has no effect on embryonic development.
e. Exposure to a hazardous substance must occur for at least 5 years to affect female fertility.
6. Which of the following statements is (are) true?
a. Exposure to ionizing radiation can cause male infertility.
b. Workplace exposures to teratogens occur most often through ingestion of drinking water.
c. If exposure to a reproductive toxicant occurs at work, the only solution for a woman planning to become pregnant
is a job transfer.
d. Folic acid supplements in women of reproductive age may help prevent fetal neural tube defects.
e. Engineering controls in an occupational setting can reduce exposures to reproductive hazards.
7. If your patient is pregnant and has been exposed to lead in her drinking water, you should:
a. tell her that lead in drinking water cannot affect her pregnancy
b. determine her blood lead level
c. discourage breast feeding in any case
d. recommend that she drink bottled water
e. immediately begin treatment with a lead chelating agent
8. Which of the following compounds are known or suspected teratogens?
a. lead
b. lithium
c. mercury
d. chlorobiphenyls or PCBs
e. 1,2-dibromo-3-chioropropane (DBCP)
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CASE STUDIES IN ENVIRONMENTAL MEDICINE: 
REPRODUCTIVE AND DEVELOPMENTAL HAZARDS
If you wish CME credits or CEU, please indicate your answers to the Posttest questions on page 40 by circling 
the letters below for the correct answers. Complete the evaluation questionnaire and fill in the information 
requested on the reverse side. Tear off this page, fold, staple, and mail to Continuing Education Coordinator, 
Agency for Toxic Substances and Disease Registry, Division of Health Education, E33, 1600 Clifton Road, NE, 
Atlanta, GA 30333.
1. a b c d e
2. a b c d e
3. a b c d e
4. a b c d e
5. a b c d e
6. a b c d e
7. a b c d e
8. a b c d e
Evaluation Questionnaire
Please complete the following evaluation by putting a check in the appropriate box.
YES
1. As a result of completing this monograph, I will be able to:
Describe the factors contributing to reproductive and developmental □
hazards.
Identify adverse reproductive and developmental outcomes that may be □  
caused by environmental or occupational exposures.
Identify evaluation and treatment protocols for adverse reproductive and □  
developmental outcomes.
List sources of information on reproductive and developmental hazards. □
2. I am more likely to ask questions about possible environmental exposures □  
as a result of reading this issue.
3. I will recommend this issue to my colleagues. □
4. I will keep this issue as a reference. □
Comments: ------------------------------------------------------------------------------------------------------------------
NO UNDECIDED
□  □
a □
a a
a a
□  □
□  □
□  □
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To obtain credit, please provide the information requested below.
Name _  
Address
---------------------------------------------------------------------- Z ip ---------------------------------
Check one:
□  CME-AMA □  CME-AAFP O  CME-ACEP □  CME-AOA
□  CEU O  Contact Hours-AAOHN □  CM-ABIH 
Specia lty______________________________________________________
To be placed on mailing list, check here. □
fold here first
PLEASE
PLACE
STAMP
HERE
Continuing Education Coordinator
Agency for Toxic Substances and Disease Registry 
Division of Health Education, E33 
1600 Clifton Road, NE 
Atlanta, GA 30333
fold here second
Please send me the following Case Studies in Environmental Medicine:
□ Arsenic □ Gasoline □ Stoddard Solvent
□ Asbestos □ Jet Fuels □ Tetrachloroethylene
□ Benzene □ Lead □ 1,1,1-Trichloroethane
□ Beryllium □ Mercury □ Trichloroethylene
□ Cadmium □ Methanol □ Toluene
□ Carbon Tetrachloride □ Methylene Chloride □ Vinyl Chloride
□ Chlordane □ Nitrates/Nitrites □ Exposure History
□ Cholinesterase Inhibitors □ Pentachlorophenol □ Risk Communication
□ Chromium □ Polyaromatic Hydrocarbons (PAHs) □ Reproductive and
□ Cyanide □ Polychlorinated Biphenyls (PCBs) n
Developmental Hazards 
Skin Lesions
□ Dioxins □ Radiation
i—i
□  Ethylene/Propylene Glycols □ Radon
staple or tape
C E N T E R S  FO B D K U H  CO N TR O L A N D  P R EV E N T IO NC D C  I N F O R M A T I O N  C E N T E R
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The stale of knowledge regarding the treatment of patients potentially 
exposed to hazardous substances in the environment is constantly evolving 
and is often uncertain. In this monograph, the Agency for Toxic Substances 
and Disease Registry (ATSDR) has made diligent effort to ensure the accuracy 
and currency of the information presented but makes no claim that the 
document comprehensively addresses all possible situations related to this 
topic. This monograph is intended as an additional resource for physicians 
and other health professionals in assessing the condition and managing the 
treatment of patients potentially exposed to hazardous substances. It is not, 
however, a substitute for the professional judgment of a health care provider 
and must be interpreted in conjunction with other sources of authority and in 
light of specific patient information available to such a professional.
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